ENTR 601 44
Alternative Names: ENTR-601-44; Exon 44 Skipping Oligonucleotide - Entrada TherapeuticsLatest Information Update: 27 Jun 2024
At a glance
- Originator Entrada Therapeutics
- Class Drug conjugates; Oligonucleotides
- Mechanism of Action Nucleic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Duchenne muscular dystrophy
Most Recent Events
- 24 Jun 2024 Pharmacokinetics and adverse events data from the phase I trial in Duchenne muscular dystrophy release by Entrada Therapeutics
- 13 Mar 2024 Entrada Therapeutics announces intention to submit a regulatory application for a phase II trial in Duchenne muscular dystrophy in the fourth quarter of 2024
- 08 Aug 2023 Phase-I clinical trials in Duchenne muscular dystrophy (In volunteers) in United Kingdom (IV)